{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T08:16:43Z","timestamp":1765873003481,"version":"3.48.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,16]]},"DOI":"10.7759\/cureus.99347","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T08:14:25Z","timestamp":1765872865000},"source":"Crossref","is-referenced-by-count":0,"title":["Metabolic Dysfunction-Associated Steatohepatitis With Positive Antimitochondrial M2 Antibodies: Diagnostic Pitfall and Importance of Follow-Up"],"prefix":"10.7759","author":[{"given":"Sara","family":"Mounsif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Bahlaoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanane","family":"Delsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wafaa","family":"Khannoussi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imane","family":"Ben El Barhdadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","unstructured":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024, 81.492-542. 10.1016\/j.jhep.2024.04.031","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2024.02.007","article-title":"Current status and future trends of the global burden of MASLD","volume":"35","author":"Miao L","year":"2024","unstructured":"Miao L, Targher G, Byrne CD, Cao YY, Zheng MH. Current status and future trends of the global burden of MASLD. Trends Endocrinol Metab. 2024, 35:697-707. 10.1016\/j.tem.2024.02.007","journal-title":"Trends Endocrinol Metab"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08904-y","article-title":"Antimitochondrial antibodies: from bench to bedside","volume":"63","author":"Colapietro F","year":"2022","unstructured":"Colapietro F, Lleo A, Generali E. Antimitochondrial antibodies: from bench to bedside. Clin Rev Allergy Immunol. 2022, 63:166-77. 10.1007\/s12016-021-08904-y","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.0405-17","article-title":"A young man with non-alcoholic steatohepatitis and serum anti-mitochondrial antibody positivity","volume":"57","author":"Seike T","year":"2018","unstructured":"Seike T, Komura T, Shimizu Y, et al.. A young man with non-alcoholic steatohepatitis and serum anti-mitochondrial antibody positivity. Intern Med. 2018, 57:3093-7. 10.2169\/internalmedicine.0405-17","journal-title":"Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000002785","article-title":"Coexistence of metabolic-associated fatty liver disease and autoimmune or toxic liver disease","volume":"36","author":"Danielsson O","year":"2024","unstructured":"Danielsson O, Vesterinen T, Arola J, \u00c5berg F, Nissinen MJ. Coexistence of metabolic-associated fatty liver disease and autoimmune or toxic liver disease. Eur J Gastroenterol Hepatol. 2024, 36:961-9. 10.1097\/MEG.0000000000002785","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18134","article-title":"The overlap with metabolic dysfunction-associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis","volume":"60","author":"Hern\u00e1ndez-P\u00e9rez M","year":"2024","unstructured":"Hern\u00e1ndez-P\u00e9rez M, Riado D, Pena E, et al.. The overlap with metabolic dysfunction-associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis. Aliment Pharmacol Ther. 2024, 60:613-9. 10.1111\/apt.18134","journal-title":"Aliment Pharmacol Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000036039","article-title":"Diagnostic value of anti-mitochondrial antibody in patients with primary biliary cholangitis: a systemic review and meta-analysis","volume":"102","author":"Xu Q","year":"2023","unstructured":"Xu Q, Zhu W, Yin Y. Diagnostic value of anti-mitochondrial antibody in patients with primary biliary cholangitis: a systemic review and meta-analysis. Medicine (Baltimore). 2023, 102:e36039. 10.1097\/MD.0000000000036039","journal-title":"Medicine (Baltimore)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017, 67:145-72. 10.1016\/j.jhep.2017.03.022","journal-title":"J Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13111840","article-title":"Detection of M2-type anti-mitochondrial autoantibodies against specific subunits in the diagnosis of primary biliary cholangitis in patients with discordant results","volume":"13","author":"Arnaldos-P\u00e9rez C","year":"2023","unstructured":"Arnaldos-P\u00e9rez C, P\u00e9rez-Isidro A, Bolos U, et al.. Detection of M2-type anti-mitochondrial autoantibodies against specific subunits in the diagnosis of primary biliary cholangitis in patients with discordant results. Diagnostics (Basel). 2023, 13:1840. 10.3390\/diagnostics13111840","journal-title":"Diagnostics (Basel)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2024.04.229","article-title":"Anticorps anti-mitochondries d\u00e9tect\u00e9s lors du typage des anticorps antinucl\u00e9aires par immunodot: quelle relevance clinique?","volume":"45","author":"Jaziri I","year":"2024","unstructured":"Jaziri I, Mejdoub S, Boudaya M, Marrakchi R, Feki S, Turki M, Hachicha H. Anticorps anti-mitochondries d\u00e9tect\u00e9s lors du typage des anticorps antinucl\u00e9aires par immunodot: quelle relevance clinique?. Rev Med Interne. 2024, 45:A258. 10.1016\/j.revmed.2024.04.229","journal-title":"Rev Med Interne"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.14744\/hf.2023.2023.0016","article-title":"The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients","volume":"4","author":"Ergenc I","year":"2023","unstructured":"Ergenc I, Gozaydinoglu B, Keklikkiran C, Yilmaz Y. The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients. Hepatol Forum. 2023, 4:69-73. 10.14744\/hf.2023.2023.0016","journal-title":"Hepatol Forum"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28859","article-title":"Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis","volume":"65","author":"Dahlqvist G","year":"2017","unstructured":"Dahlqvist G, Gaouar F, Carrat F, et al.. Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. Hepatology. 2017, 65:152-63. 10.1002\/hep.28859","journal-title":"Hepatology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-015-3795-5","article-title":"Autoimmune markers do not impact clinical presentation or natural history of steatohepatitis-related liver disease","volume":"60","author":"Ravi S","year":"2015","unstructured":"Ravi S, Shoreibah M, Raff E, Bloomer J, Kakati D, Rasheed K, Singal AK. Autoimmune markers do not impact clinical presentation or natural history of steatohepatitis-related liver disease. Dig Dis Sci. 2015, 60:3788-93. 10.1007\/s10620-015-3795-5","journal-title":"Dig Dis Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/420506-metabolic-dysfunction-associated-steatohepatitis-with-positive-antimitochondrial-m2-antibodies-diagnostic-pitfall-and-importance-of-follow-up","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T08:14:31Z","timestamp":1765872871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/420506-metabolic-dysfunction-associated-steatohepatitis-with-positive-antimitochondrial-m2-antibodies-diagnostic-pitfall-and-importance-of-follow-up"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.99347","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,16]]}}}